BR112014027870B1 - Formulação parenteral e esmolol e uma solução pronta para uso contendo a formulação de esmolol, um kit contendo dita formulação e sua produção - Google Patents

Formulação parenteral e esmolol e uma solução pronta para uso contendo a formulação de esmolol, um kit contendo dita formulação e sua produção Download PDF

Info

Publication number
BR112014027870B1
BR112014027870B1 BR112014027870-9A BR112014027870A BR112014027870B1 BR 112014027870 B1 BR112014027870 B1 BR 112014027870B1 BR 112014027870 A BR112014027870 A BR 112014027870A BR 112014027870 B1 BR112014027870 B1 BR 112014027870B1
Authority
BR
Brazil
Prior art keywords
esmolol
solution
ready
formulation
chloride
Prior art date
Application number
BR112014027870-9A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014027870A8 (pt
BR112014027870A2 (pt
Inventor
Widmann Rudolf
Original Assignee
Aop Orphan Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48407551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014027870(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aop Orphan Pharmaceuticals Gmbh filed Critical Aop Orphan Pharmaceuticals Gmbh
Publication of BR112014027870A2 publication Critical patent/BR112014027870A2/pt
Publication of BR112014027870A8 publication Critical patent/BR112014027870A8/pt
Publication of BR112014027870B1 publication Critical patent/BR112014027870B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014027870-9A 2012-05-10 2013-05-08 Formulação parenteral e esmolol e uma solução pronta para uso contendo a formulação de esmolol, um kit contendo dita formulação e sua produção BR112014027870B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12167443.6 2012-05-10
EP12167443 2012-05-10
PCT/EP2013/059594 WO2013167657A1 (en) 2012-05-10 2013-05-08 Parenteral esmolol formulation

Publications (3)

Publication Number Publication Date
BR112014027870A2 BR112014027870A2 (pt) 2017-06-27
BR112014027870A8 BR112014027870A8 (pt) 2023-01-17
BR112014027870B1 true BR112014027870B1 (pt) 2023-04-25

Family

ID=48407551

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014027870-9A BR112014027870B1 (pt) 2012-05-10 2013-05-08 Formulação parenteral e esmolol e uma solução pronta para uso contendo a formulação de esmolol, um kit contendo dita formulação e sua produção

Country Status (27)

Country Link
US (3) US20150087704A1 (enExample)
EP (1) EP2846776B1 (enExample)
JP (1) JP6220383B2 (enExample)
CN (1) CN104379134A (enExample)
AU (1) AU2013258031B2 (enExample)
BR (1) BR112014027870B1 (enExample)
CA (1) CA2872953C (enExample)
CL (1) CL2014003028A1 (enExample)
DK (1) DK2846776T3 (enExample)
EA (1) EA032344B1 (enExample)
ES (1) ES2794093T3 (enExample)
HR (1) HRP20200897T1 (enExample)
HU (1) HUE049314T2 (enExample)
IL (1) IL235497A0 (enExample)
LT (1) LT2846776T (enExample)
MA (1) MA37500B1 (enExample)
MX (1) MX374771B (enExample)
MY (1) MY173900A (enExample)
NZ (1) NZ701429A (enExample)
PH (1) PH12014502494B1 (enExample)
PL (1) PL2846776T3 (enExample)
PT (1) PT2846776T (enExample)
SI (1) SI2846776T1 (enExample)
TN (1) TN2014000464A1 (enExample)
UA (1) UA115333C2 (enExample)
WO (1) WO2013167657A1 (enExample)
ZA (1) ZA201408149B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019122157A1 (en) * 2017-12-21 2019-06-27 Ipsol Ag A lyophilisate comprising esmolol and adenosine for use in cardioplegia
CN111848420A (zh) * 2020-07-22 2020-10-30 杭州煌森生物科技有限公司 一种盐酸艾司洛尔的新晶型及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310094B1 (en) * 2001-01-12 2001-10-30 Baxter International Inc. Ready-to-use esmolol solution
TWI277414B (en) 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2007026771A1 (ja) * 2005-08-31 2007-03-08 Ono Pharmaceutical Co., Ltd. 点滴用注射剤
US20080293814A1 (en) 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
JP5623288B2 (ja) 2007-12-21 2014-11-12 エイオーピーオーファン ファーマスーティカルズ アクチエンゲゼルシャフトＡＯＰ Ｏｒｐｈａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 医薬組成物
CN102106846A (zh) * 2009-12-23 2011-06-29 南京海辰药业有限公司 左旋盐酸艾司洛尔药物组合物及其制备方法

Also Published As

Publication number Publication date
CN104379134A (zh) 2015-02-25
US20150087704A1 (en) 2015-03-26
CA2872953A1 (en) 2013-11-14
TN2014000464A1 (en) 2016-03-30
MX2014013556A (es) 2015-01-16
AU2013258031B2 (en) 2017-08-03
MY173900A (en) 2020-02-26
EP2846776B1 (en) 2020-04-15
SI2846776T1 (sl) 2020-08-31
EA201491841A1 (ru) 2015-02-27
PH12014502494B1 (en) 2019-11-13
WO2013167657A1 (en) 2013-11-14
BR112014027870A8 (pt) 2023-01-17
IL235497A0 (en) 2014-12-31
MA37500B1 (fr) 2016-12-30
ZA201408149B (en) 2016-08-31
HUE049314T2 (hu) 2020-09-28
PL2846776T3 (pl) 2020-09-21
MA37500A1 (fr) 2016-03-31
DK2846776T3 (da) 2020-06-15
AU2013258031A1 (en) 2014-11-20
EA032344B1 (ru) 2019-05-31
BR112014027870A2 (pt) 2017-06-27
US11963940B2 (en) 2024-04-23
JP6220383B2 (ja) 2017-10-25
ES2794093T3 (es) 2020-11-17
CA2872953C (en) 2020-04-07
PH12014502494A1 (en) 2015-01-12
US20170326095A1 (en) 2017-11-16
US20220249424A1 (en) 2022-08-11
CL2014003028A1 (es) 2015-06-19
EP2846776A1 (en) 2015-03-18
UA115333C2 (uk) 2017-10-25
HRP20200897T1 (hr) 2020-11-27
HK1204265A1 (en) 2015-11-13
JP2015520142A (ja) 2015-07-16
PT2846776T (pt) 2020-05-28
MX374771B (es) 2025-03-06
NZ701429A (en) 2016-04-29
LT2846776T (lt) 2020-06-25

Similar Documents

Publication Publication Date Title
US20240207365A1 (en) Methods for producing stable therapeutic formulations in aprotic polar solvents
JP6888091B2 (ja) スルホニル尿素系薬の医薬組成物及びその調製方法
JP2018531268A (ja) ダントロレンを含む水性組成物
JP2018531268A6 (ja) ダントロレンを含む水性組成物
US20250170151A1 (en) Low-sorbing glyburide kit, formulation and methods
JP2024510156A (ja) 安定したドセタキセルアルブミンナノ粒子組成物
US11963940B2 (en) Parenteral esmolol formulation
CA3210407A1 (en) Low-sorbing glyburide formulation and methods
US10238717B2 (en) Parenteral glucagon formulations
ES2290575T3 (es) Concentrados de soluciones de oxaliplatino.
BRPI0418005B1 (pt) composição farmacêutica de vinflunina, utilização de uma composição, e, processo de preparação de uma composição
CN102885766B (zh) 一种右旋酮洛芬注射液及其制备方法
HK1204265B (en) Parenteral esmolol formulation
CN121154534A (zh) 一种依托考昔注射液及其制备方法
KR101327904B1 (ko) 목시플록사신 염산염의 주사제형
WO2020025986A1 (en) Injectable combination of diclofenac sodium and thiocolchicoside
BR122025015489A2 (pt) Métodos para produzir formulações terapêuticas estáveis em solventes apolares apróticos
CN101366701A (zh) N，n-二甲基甘氨酸-2，6-二异丙基苯酯盐类注射剂

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.2 NA RPI NO 2552 DE 03/12/2019 POR TER SIDO INDEVIDA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: AOP ORPHAN PHARMACEUTICALS GMBH (AT)

B25G Requested change of headquarter approved

Owner name: AOP ORPHAN PHARMACEUTICALS GMBH (AT)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/05/2013, OBSERVADAS AS CONDICOES LEGAIS